Philip Morris International: In-Depth Value Investment Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  Bottom line: PM is mainly "expanding and re-slicing an existing pie," rather than creating a brand-new market from scratch. What it is doing is moving existing nicotine consumers from combustible cigarettes to its own smoke-free products (IQOS, ZYN, VEEV). Its ceiling is therefore constrained by the existing global nicotine population and country-level regulation, not by a new growth curve that can be extrapolated without limit.

  Start with the size of the pie itself, and where it is going. The report's more accurate description of the overall nicotine industry is "structural migration inside a mature industry": combustible tobacco is in long-term decline in most markets, while smoke-free products grow through substitution. The company itself acknowledges this. PMI expects total international cigarette and HTU industry volume outside China and the U.S. to still decline by about 2% in 2026. In other words, PM is not breaking ground in untouched territory. It is competing for value in a slowly shrinking pool by moving consumers from "combustion" to "non-combustion." The so-called "ceiling" is essentially "how much of the existing cigarette share smoke-free substitution can absorb," rather than "how much unprecedented new demand it has created."

  The migration runway is still meaningful, and that is the core of the bull case for PM. The smoke-free business has moved from concept to reality: in 2025, smoke-free products contributed $1.69 billion in net revenue and 41.5% of total net revenue (note: this should be $16.854 billion, consistent with the report's framework), and by 2026 Q1, smoke-free had reached 43% of total net revenue, with estimated adult consumers exceeding 43 million. The company's medium-term target is to push the smoke-free share toward 50%+. Given that the world still has roughly 1 billion smokers, and that IQOS has already become the largest nicotine "brand" in its markets, converting cigarette users into smoke-free users still has several years of depth. This is the fundamental reason PM's valuation has diverged from that of a pure cigarette company.

  But three hard constraints on the ceiling have to be stated plainly, and they are also why I do not treat this as "creating a new market." First, the conversion target is existing users, not new demand: much of the growth in smoke-free products comes from cannibalizing cigarette share from PM itself and peers. It is a value migration from one pocket to another, while the overall nicotine population in developed markets is in long-term contraction. Second, the ceiling is directly capped by regulation: this is not a market that product innovation can expand indefinitely. Restrictions on flavors, marketing, nicotine strength, youth access, and MRTP claims can slow growth at any time, which is exactly why the report lists regulatory risk as the "first risk." Third, the latest quarter has already shown what the ceiling feels like in practice: in 2026 Q1, in the U.S. market, ZYN shipments fell 23.5%, and U.S. segment net revenue fell 30.8% (although Nielsen-measured consumer offtake still grew by about 10%). This shows that even in its strongest smoke-free lane, share can be squeezed in very real terms by rivals such as BAT and Japan Tobacco. There is no "natural monopoly" style unlimited expansion.

  Overall judgment: this is an existing pie that is "large enough, with migration still having depth," and it genuinely gives PM more growth than pure cigarette peers. But it is not a newly created market. The ceiling is jointly locked by the existing global nicotine population and regulation. Upside imagination has boundaries and is highly policy-sensitive. Through the Baillie LTGG lens, PM is a strong student that "cuts the existing pie better in a difficult industry," not the kind of ten-year five-bagger candidate that "opens a new continent." Growth is driven by structural migration: meaningful but capped, not exponential and open-ended.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?4/10

  A

  Bottom line: almost certainly not. For PM to double revenue within five years (from about $40.6 billion in 2025 to more than $80 billion), it would need a CAGR of about 15%, far above its historical and current pace. In reality, growth is jointly driven by "price" (cigarette price increases) and "new business" (smoke-free volume growth), with limited contribution from volume. Together they can support roughly mid-single-digit to high-single-digit growth, but not a doubling.

  First, calibrate the scale using history. The report states that PM revenue rose from $31.405 billion to $40.648 billion in 2021-2025, a cumulative increase of about 29% over four years, or about 6.6% annualized. Full-year 2025 net revenue was $4.06 billion, up 7.3% year on year (should be $40.6 billion). A mature consumer company that at its fastest only managed single-digit growth over the past four years has no business basis for more than doubling the slope to 15% over the next five years.

  Now look at the real slope in the latest quarter, which is more revealing than annual report figures. In 2026 Q1, net revenue grew 9.1% as reported, but organic growth excluding currency and M&A was only 2.7%. A large part of the 9.1% came from the weak dollar as a currency tailwind, not endogenous momentum. Organic total revenue growth of 2.7% is an order of magnitude away from the 15% needed to double.

  Breaking down the sources of growth, the ceiling of each of the three engines is clear:

  First, price (cigarette price increases). This is PM's most stable cash-cow driver: in 2025, the combustible business still grew net revenue by 2.5% despite cigarette shipments falling 1.5% year on year, entirely through net pricing management. But price increases mean "exchanging shrinking volume for a higher unit price." Over the long term, they can only contribute low-single-digit growth and cannot drive a doubling.

  Second, volume + price (the new smoke-free business). This is the real growth engine, and its quality is decent: in 2025, smoke-free net revenue grew 15.0%, with heated tobacco units up 11.0% and nicotine pouch shipments up 36.6%. But smoke-free is only 41.5% of total revenue. Even if it continues to grow at 15%, its pull on the whole company is heavily diluted by cigarettes, which account for 58%, grow only 2%-3%, and still face volume decline. A rough calculation: if smoke-free compounds at 15% for five years and combustibles grow at 2%, total revenue would cumulatively rise only about +40%, still far short of the +100% line for doubling.

  Third, the fragility of the new business has already been exposed. Smoke-free growth is not a one-way march: in 2026 Q1 in the U.S., ZYN shipments fell 23.5%, and U.S. segment net revenue fell 30.8%, leading the company to lower parts of its Q2 and full-year guidance. Even if management explains this as channel inventory normalization (with consumer offtake still up about 10%), it reminds us that the growth engine can be interrupted by competition (BAT, Japan Tobacco) and regulatory uncertainty. It is even less likely to double linearly.

  One fair comparison on profitability: revenue will not double, but earnings quality is improving faster than revenue. The company's 2026 full-year adjusted EPS guidance of $8.36-$8.51, up 10.9%-12.9% year on year, is driven by structural mix improvement from higher-gross-margin smoke-free products. So "earnings may cumulatively grow by around 50% over five years" is reasonable, but that is different from the question's "revenue doubling" and cannot be conflated.

  Overall judgment: PM revenue doubling over the next five years is unrealistic. A reasonable expectation is mid-single-digit to high-single-digit annualized revenue growth (closer to 2%-5% organic on a currency-neutral basis, potentially higher in total after smoke-free mix improvement). The drivers are the combination of "cigarette price increases + smoke-free volume growth"; volume itself, especially cigarette volume, is a headwind. Measured against Baillie's hard threshold of "can revenue double in five years," PM clearly does not qualify. It is a high-quality cash-compounding machine, but not a growth machine with exponential revenue expansion.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this "second curve" exist today?5/10

  A

  Bottom line: PM's "second curve" already exists today and is being monetized. It is the smoke-free business made up of IQOS + ZYN + VEEV. But this curve is essentially "the successor to the cigarette cash cow," not "a third new engine beyond smoke-free." The real concern is that five years from now, when smoke-free also enters maturity, PM currently does not show a clear next growth pole outside smoke-free.

  First, confirm that the second curve is real, not a slide-deck story. The smoke-free business has moved from "transformation story" to "cash-flow reality": in 2025, smoke-free products generated $16.854 billion in net revenue, 41.5% of total net revenue, and grew 15.0% year on year; by 2026 Q1, its share had risen to 43%. This curve also has three relay layers across its pillars:

  First leg (mature, still growing): IQOS heated tobacco. This is the largest and most certain part of smoke-free, with about 77% volume share in the global heat-not-burn category, and in 2026 Q1, IQOS surpassed Marlboro to become the largest nicotine brand in its markets. IQOS also has the U.S. market, a runway not yet truly opened (previously blocked by patent litigation), as visible incremental growth over the next few years.

  Second leg (scaling, with recent volatility): ZYN oral nicotine pouches. In 2025, nicotine pouch shipments grew 36.6%, and ZYN maintained about two-thirds value share in the U.S.. But it has recently exposed fragility: in 2026 Q1, ZYN shipments fell 23.5% (the company attributes this to channel inventory normalization, while consumer offtake still rose about 10%). This shows that the second leg can run, but not in a perfectly smooth line.

  Third leg (potential, not yet established): VEEV e-vapor. The report lists VEEV as one of the three major smoke-free axes, but openly acknowledges that "VEEV failing to form a second growth curve" is one bearish scenario. In other words, VEEV is still small, far less important than IQOS/ZYN, and whether it can become a meaningful growth pole remains an open question.

  The key honest judgment: this second curve is a "replacement for cigarettes," not "a new business beyond smoke-free." The report puts it plainly: PM's current investment logic is "no longer just a cigarette money printer, but smoke-free taking over from cigarettes." In other words, IQOS/ZYN are taking the baton from declining combustible tobacco. At heart, this remains structural migration inside the same nicotine pool (see this report's answer on the "market ceiling"). Once smoke-free penetration reaches a high level and cigarettes have little room left to fall, PM may be re-rated from a "transformation growth stock" back to a "high-quality but low-growth tobacco company." This is exactly the core of the "business model substitution risk" identified by the report: if over 3-5 years ZYN loses share, IQOS is squeezed, and VEEV fails to scale, PM's valuation premium can fall back quickly.

  So where is the "next engine five years from now"? What the report and the company can currently point to is still mainly depth inside smoke-free (IQOS entering the U.S., ZYN going international, VEEV scaling), plus early exploration in a small number of wellness products. But there is no clear new engine outside smoke-free with comparable scale. This is fundamentally different from the companies Baillie tends to favor, where new platforms can keep growing on top of the core business (for example, businesses with data/network spillovers and unlimited extension into adjacent categories). PM's regenerative capacity is locked inside the single category of nicotine, which is itself constrained by regulation and social license over the long term.

  Overall judgment: the second curve does exist and is being monetized (smoke-free 43%, IQOS global No. 1), which is PM's biggest advantage over pure cigarette peers. But it is a "succession" rather than a "new opening," and after smoke-free matures in five years, there is no clear third engine. From Baillie's perspective, PM scores decently on "does the second curve exist," but is clearly constrained on "can it keep growing new curves, and is upside imagination open-ended." This curve has an endpoint, and the story beyond that endpoint has not yet been written.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Bottom line: PM's core moat is not a single patent. It is the combination of "super brands + global-scale manufacturing and distribution + regulatory compliance/scientific submission capability + nicotine consumption habits." Over the next three to five years, the old cigarette moat will keep narrowing at the level of social license, but PM is converting it into a moat around a "compliant smoke-free nicotine platform." The net effect is roughly "stable to slightly wider," provided IQOS/ZYN leadership and regulatory standing do not suffer a major reversal.

  First, what makes up the moat, and where is it strong? The report breaks this down clearly. The truly hard barriers are:

  Brand (strong). Marlboro remains the world's best-selling international cigarette brand, accounting for about 43% of PM's 2025 cigarette shipments, while the top five brands together account for 81% of shipments; on the new-product side, IQOS and ZYN already have brand-platform characteristics.

  Scale and channels (strong). Cigarettes cover about 170 markets, and smoke-free products cover 108 markets. Combined with a global R&D and manufacturing network, this is itself a barrier that later entrants cannot replicate quickly.

  Regulatory/license barrier (strong). This is an underestimated one: in 2025, ZYN received FDA marketing authorization for 20 products, and the IQOS/HEETS "reduced exposure" MRTP authorization was renewed by the FDA in 2026. Replicating a system that already has global distribution, scientific submission capability, regulatory approval, and brand-building ability is much harder than copying an ordinary consumer brand. The report therefore gives moat strength a 4/5.

  Pricing power (real). In 2025, the combustible business still grew net revenue by 2.5% despite cigarette shipments falling 1.5%, proving that profit comes from net price management rather than volume growth.

  The weaknesses also need to be clear: network effects are weak (PM is not a platform company), switching costs are only medium (consumers are legally free to switch, with the hidden cost coming from nicotine habits and brand preference), and the data advantage is medium to weak. So this is a "brand + scale + regulation" moat, not a "network + data + ecosystem lock-in" moat. That makes it solid, but without a self-reinforcing flywheel.

  Will it widen or narrow over the next three to five years? This has to be separated into two lines, which is exactly the key to "time-slicing":

  The narrowing side (historical indicators only prove what used to be true). The cigarette moat is structurally narrowing at the level of social license: long-term demand migration, anti-smoking litigation, taxes, and flavor/marketing restrictions only increase. The report lists regulation as the first risk. Any tightening around flavors, youth access, nicotine strength, or MRTP claims could weaken the moat.

  The widening side (looking at forward marginal evidence). PM is migrating the narrowing cigarette barriers into smoke-free platform barriers, and the marginal evidence is positive: IQOS has about 77% global heated tobacco volume share and surpassed Marlboro in 2026 Q1 to become the largest nicotine brand in its markets, while ZYN has FDA authorization and maintains about 2/3 value share in the U.S. If competitors want to replicate the same position, the report judges that they would need years, billions of dollars in investment, and still might not receive equivalent regulatory outcomes.

  But widening is not guaranteed. Cracks have already appeared in the latest quarter. In 2026 Q1 in the U.S., ZYN shipments fell 23.5%, and U.S. segment net revenue fell 30.8%, behind which competition is intensifying from BAT in U.S. nicotine pouches and Japan Tobacco in heated tobacco. This reminds us that the "width" of the smoke-free moat has to be proven by share every quarter. Forward-looking analysis cannot simply extrapolate historical leadership in a straight line. The report's falsification signals are exactly these: if "ZYN's U.S. value share falls materially from about 2/3" or "IQOS share stops rising or is eroded in Japan/Europe," the moat assessment should be revised downward.

  Overall judgment: PM has a real, profit-converting strong moat (4/5), and it is completing the migration of its moat from cigarettes to smoke-free. Over three to five years, the net effect leans "stable to slightly wider." But it lacks the self-reinforcing flywheel of a network/data moat; its width depends heavily on two external variables, share and regulation, and competitors have already launched substantive attacks in its strongest lanes. By Baillie's yardstick, this moat is deep enough and durable enough, but it is the kind of high-quality barrier that can be defended, not the kind that widens with use and compounds by itself. It can protect cash flow, but it cannot by itself carry the company to a ten-year five-bagger.

  Jun 11, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Bottom line: PM has already proven through one act of "self-disruption" that it has the DNA to reinvent itself. It did not cling to the combustible cigarette money printer, but proactively migrated the core business toward smoke-free, and that migration has been monetized at scale. Its handling of bad news and mistakes also appears relatively mature (truthful disclosure and responsiveness to governance feedback). But this DNA is locked inside the single category of "nicotine." If one day overall nicotine demand is fundamentally disrupted, rather than merely cigarettes being replaced by smoke-free products, PM has almost no precedent or assets showing it can reinvent itself outside the category.

  Start with the strongest positive evidence for "reinvention DNA": PM is one of the few tobacco companies that has actively disrupted its own cash cow. Instead of, like many traditional tobacco companies, relying on price increases to squeeze cigarettes until the last moment, it has invested more than $16 billion cumulatively in smoke-free products since 2008, putting that money behind IQOS, which cannibalizes its own cigarettes. The result: smoke-free already accounted for 41.5% of net revenue in 2025 and reached 43% in 2026 Q1, while IQOS has about 77% share in the global heat-not-burn category. The report comments that "making a successful smoke-free transformation on top of traditional tobacco is not easy," and rates corporate culture/operating capability as "relatively strong." A company willing to feed its new business with share from its cash cow has a rare willingness to reinvent itself.

  Self-expansion through M&A also supports this DNA. The 2022 acquisition of Swedish Match (ZYN) raised debt and goodwill, but the report judges it "strategically very successful." It gave PM a direct leading position in the U.S. oral nicotine pouch lane, with ZYN maintaining about two-thirds value share in the U.S. and receiving FDA marketing authorization in 2025 for products already on sale. This shows that PM does not merely wait passively for its core to be disrupted. It will proactively acquire to fill out the second curve.

  Now look at "how it treats mistakes and bad news," a touchstone for management honesty. PM's performance is on the positive side:

  First, it responds to governance criticism. The report notes that after say-on-pay support fell in 2022 and 2023, the company strengthened investor communication, and support recovered to 92.88% and 95.38% in 2024 and 2025. Receiving a negative signal, adjusting, and rebuilding support shows feedback and correction capability at the governance level.

  Second, it discloses bad news frankly and does not hide it. The company separately presents restructuring, Germany tax litigation, Canadian RBH matters, and fair-value changes in equity investments in its financial reports. The report therefore concludes, "I have not seen obvious signs of fraud... there is management-framework optimization, but cash flow can still verify through the statements." The latest quarter's bad news was not hidden either: in the U.S., ZYN shipments fell 23.5%, and U.S. segment net revenue fell 30.8%, and the company proactively lowered parts of Q2 and full-year guidance rather than dressing it up. Facing bad news and cutting guidance is a mature response, not avoidance.

  But the boundary of this DNA has to be stated honestly. This is the hidden premise investors should watch most carefully: PM's reinvention ability is locked inside the nicotine category. All of PM's "reinventions" so far, IQOS, ZYN, and VEEV, are still nicotine products. Only the delivery method has shifted from combustion to heating/oral/vapor. It has proven the ability to move from combustible to smoke-free inside nicotine, but it has never proven that when overall nicotine demand is disrupted (for example, a global sales ban, strict regulation of nicotine itself, or social de-nicotinization), it can jump into an unrelated category and be reborn. The report lists this kind of terminal risk as one of the three major concerns for bears: "tobacco's terminal risk has not disappeared." The company has some small wellness explorations, but they are tiny and far from enough to constitute out-of-category reinvention capability.

  Two additional reservations on the correction culture: management and shareholders are not bound by very large personal ownership (all directors and officers together own less than 1% of total shares outstanding, and the CEO holds about 500 thousand shares), relying more on compensation and governance constraints; the company sometimes emphasizes adjusted EPS (the 60.6% jump in 2025 GAAP EPS partly reflected a low base and comparability effects), so investors should look more at cash flow and less at adjusted "pretty numbers." This is not fraud, but it shows that the correction culture contains some "narrative management."

  Overall judgment: on "in-category self-disruption," PM has delivered rare real results among peers, and its handling of mistakes and bad news is relatively mature and honest. Its reinvention DNA is solid inside nicotine. But that DNA has not and need not have proven the ability to "be reborn outside nicotine." If it faces category-level disruption, its regenerative capacity is questionable. By Baillie's yardstick, PM scores in the upper middle on "can it evolve when the core is replaced," but this is the ability to "change weapons on a familiar battlefield," not the ability to "move to a new battlefield and be reborn."

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for five to ten years out?4/10

  A

  Bottom line: PM has no founder. It is a mature large company run by professional managers. The degree of "deep alignment" between management and shareholders is only medium, created by compensation design, long-term equity incentives, and ownership requirements rather than very large personal ownership. It has indeed shown willingness to "sacrifice the present for five to ten years out" by actively feeding the smoke-free transition with cash-cow share, which is a real bright spot. But this long-termism comes from strategic judgment and governance systems, not from founder-style "personal wealth tied to the company."

  First, be clear about the degree of alignment, because this is the biggest gap versus the founder-led companies favored by Baillie. The report states that Jacek Olczak has served as CEO since 2021, and the 2026 proxy shows he holds about 500,844 company shares. At the current share price of about $183, that is roughly $90 million in market value, a large absolute amount but immaterial relative to PM's market value of about $285 billion. More importantly, all directors and officers together still own less than 1% of total shares outstanding. The report's qualitative assessment is accurate: this is "not the kind of founder-led management team with very high ownership and full integration with shareholders"; alignment "does not come from very large personal ownership, but more from compensation systems, long-term equity incentives, and governance constraints." For Baillie's preference for "management as major shareholders, naturally aligned with minority shareholders," this is a structural deduction.

  But the governance system is relatively positive and should not be dismissed just because the company is not founder-led. Specific evidence includes: the company sets high stock ownership requirements for executives, with the highest-level executives required to hold stock equal to 10 times salary; the CEO does not participate in setting his own compensation; after say-on-pay support fell in 2022 and 2023, the company strengthened investor communication, and support recovered to 92.88% and 95.38% in 2024 and 2025. These details show some governance sensitivity and feedback capability. The report therefore gives "management and capital allocation" 3.5/5: credible, but not top-tier.

  Now look at the core question: is it willing to sacrifice current profits for five to ten years out? On this, PM actually performs better than its ownership alignment, with concrete evidence:

  First, it actively fed the future with cash-cow share. PM has invested more than $16 billion cumulatively in smoke-free products since 2008, putting money behind IQOS, which cannibalizes its own high-margin cigarettes. This is a classic case of "sacrificing the present and betting on the long term." The result is that smoke-free has already reached 43% of 2026 Q1 net revenue.

  Second, capital allocation has been restrained during a high-leverage period and tilted toward the long term. The report judges capital allocation over the past three years as "generally rational": after the Swedish Match acquisition, the company did not repurchase aggressively, instead using more cash for dividends and debt reduction. In 2025, the dividend rose to $5.64 per share, with $8.6 billion in dividends paid, but the company did not restart large-scale buybacks to "beautify EPS." The report even states, "At today's valuation, I would rather see it repurchase less and pay down more debt," and the company's actual behavior aligns with that long-term preference.

  Reservations should also be stated without overstating the case: first, leverage remains elevated, with $48.8 billion of total debt at the end of 2025, rising to about $51.9 billion in 2026 Q1 (net debt/EBITDA currently about 2.61 times, improved from the 3.05 times cited in the report). This means long-term investment is being done with borrowed money, not purely internal funds. Second, the company sometimes emphasizes adjusted EPS; the 60.6% rise in 2025 GAAP EPS included low-base and comparability effects, so there is an element of "narrative management." The report therefore reminds investors to look more at cash flow and less at adjusted measures.

  Overall judgment: PM's management is credible, governance-disciplined, and has proven long-termism through actions (willing to sacrifice current cigarette profit for smoke-free positioning ten years out). But it is not founder-led. Alignment is created by systems, not by personal wealth, and combined ownership is below 1%. Using Baillie's three-part test of "founder long-term view, deep alignment, willingness to sacrifice today for five to ten years out": PM answers the third well, but clearly does not match the first two. This is an excellent "stewardship" team, not an "owner" team sitting in the same boat as you.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society and regulation?4/10

  A

  Bottom line: on "how much customers would miss it," PM's addictive products create extremely high repeat-purchase stickiness, and consumers would indeed have difficulty leaving its brands in the short term. But on "whether the growth model is sustainable and not dependent on harming society and regulation," this is exactly PM's sharpest weakness. Its whole business is built on a widely recognized harmful addictive product, and growth depends to a meaningful degree on social and regulatory tolerance. It is an "excellent company in a bad industry." The two dimensions are one positive and one negative, and they have to be answered separately and honestly.

  First, indispensability (how much customers would miss it). PM is strong on this item, but the source of that strength has to be understood clearly:

  Repeat-purchase stickiness comes from addiction, not just preference. The report notes that PM revenue is highly recurring, "not because of contractual lock-in, but because consumption habits and brand preferences create high-frequency repeat purchases." In results, revenue rose from $31.405 billion to $40.648 billion in 2021-2025, and even with long-term cigarette decline, total revenue and cash flow remained resilient. The foundation of this stickiness is nicotine addiction, which keeps demand stable even during economic slowdowns. The report says "the frequency and stickiness of nicotine consumption usually allow it to generate cash flow even during economic slowdowns."

  There is also real brand preference and leadership. Marlboro remains the world's best-selling international cigarette brand, accounting for about 43% of 2025 cigarette shipments; in smoke-free, IQOS has about 77% share in the global heat-not-burn category and surpassed Marlboro in 2026 Q1 to become the largest nicotine brand in its markets, while ZYN has about two-thirds value share in the U.S.. If PM disappeared tomorrow, loyal users would strongly miss those specific brands in the short term (flavors, device ecosystem, habits).

  But the nature of this indispensability has to be named: it is "addiction-driven indispensability," not "value-creation-driven indispensability." Consumers' "missing" the product is largely driven by addiction, not by the product creating positive value in their lives. This is fundamentally different from the Baillie ideal of "if it disappeared, the world would genuinely be worse and customers would lose a beneficial service." At the same time, the report rates switching costs as only "medium": consumers are legally free to switch brands or even quit, so indispensability is not unbreakable.

  Now look at sustainability (whether it depends on harming society and regulation), which is PM's structural weakness:

  The growth of the whole business partly depends on social and regulatory tolerance. The report's industry judgment is direct: "This is not a good company in a good industry, but an excellent company in a bad industry"; "tobacco/nicotine naturally carries the shadow of regulation, litigation, social controversy, and long-term demand migration," and industry attractiveness receives only 3/5. The suitable investor base is explicitly limited to those "able to tolerate regulatory and ESG controversy," and it is "not very suitable for funds with strong ESG constraints." This is effectively an admission that the growth model is tied to controversy around "harm to society."

  Regulation is a sword hanging overhead, and it is already tightening. The report lists regulation as the first risk: "any tightening around flavors, marketing, youth access, nicotine strength, or MRTP claims could affect the pace of growth and the valuation premium." This is not an abstract concern. In 2026 Q1, the U.S. market already faced a "challenging competitive and regulatory environment," which led to a 23.5% decline in ZYN shipments and a 30.8% decline in U.S. segment net revenue. Whether growth can continue is directly tied to the attitude of the FDA and regulators in other countries.

  Long-tail legal and public-policy risks are measured in years. The report states that in 2025, a Canadian court approved a roughly C$32.5 billion settlement for Big Tobacco, involving PM's Canadian affiliate RBH; the company also continues to disclose material uncertainties related to taxes, product classification, and promotional restrictions in its 10-K. Historical bills for "harm to society" can recur over many years.

  To be fair, PM's smoke-free transformation has some legitimacy as a "harm reduction" narrative: moving addicted users from combustion to lower-risk delivery forms, while receiving FDA marketing authorization for 20 ZYN products and renewal of IQOS MRTP "reduced exposure" authorization. This makes its growth model more defensible than pure cigarettes, but it still has not escaped the fundamental controversy of nicotine addiction.

  Overall judgment: customer missingness is high (addiction + strong brands bring extremely sticky repeat purchases), and that is true. But the sustainability of this business's growth depends heavily on social and regulatory tolerance, and it is built on a widely recognized harmful addictive product. That is its largest structural flaw. Using Baillie's dual test of "how much customers would miss it + whether growth is sustainable without harming society": PM scores high on the first half and clearly low on the second. Its indispensability comes from addiction rather than value creation; the legitimacy of its growth is always under the shadow of regulatory and moral controversy. This is why the report repeatedly emphasizes "regulatory and ESG controversy" as its core risk.

  Jun 11, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate with scale? Where does the money it earns go?8/10

  A

  Bottom line: PM's unit economics are excellent: high gross margin, low capital intensity, strong cash conversion, and as smoke-free products become a larger share, unit economics improve rather than deteriorate with scale (mix upgrade lifts gross margin and profit margin). The money it earns mainly goes to three places: dividends, debt reduction, and capacity expansion for the smoke-free business. At the current stage, the company is deliberately repurchasing less and paying down more debt, so capital allocation is relatively rational.

  Start with how good the unit-economics foundation is. In 2025, PM had net revenue of $40.648 billion and operating income of $14.892 billion, corresponding to a gross margin of about 67.1% and an operating margin of about 36.6% (report framework). Capex was only $1.6 billion, less than 4% of revenue. This means it is not an asset-heavy expansion business, but one driven by brand, channels, regulatory licenses, and scale manufacturing. High gross margin + low capex is textbook high-quality unit economics.

  Incremental returns (does it become more profitable as it grows, or need more money): PM is closer to "more profitable as it grows," with conditions. The report is clear: current growth "mainly comes from smoke-free products with higher gross margin, stronger brand power, and more controllable regulation, rather than grabbing volume through low prices"; 2025 capex mainly supported smoke-free manufacturing capacity, but remained far below operating cash flow. In other words, PM's transformation "is not the kind of transformation that requires long-term cash burn to gain market share." This is a sharp contrast with many growth stocks that need sustained heavy reinvestment to maintain growth. PM's incremental capital needs are low.

  The direct evidence that unit economics improve with scale comes from mix upgrade. Smoke-free products have higher earnings quality than cigarettes: in 2025, smoke-free accounted for 41.5% of net revenue but contributed nearly 43% of gross profit, showing that smoke-free has higher unit gross profit. This structural migration directly lifts overall margins. In 2026 Q1, the international smoke-free business saw gross profit growth of 28.6% (19.4% organic), faster than its net revenue growth, reflecting both scale and mix leverage. On the earnings side, full-year 2026 adjusted EPS guidance of $8.36-$8.51, up 10.9%-12.9% year on year, means earnings growth is faster than revenue growth, exactly the sign that unit economics improve with scale.

  Capital returns confirm the strength of the unit economics. Using the report's standardized framework, PM's current ROA is about 17.8% and ROIC about 26.6%, well above BAT's ROA/ROIC of about 6.9%/7.9% and close to Altria's 24.2%/28.9%. (Note: ROE is distorted and unusable for PM because shareholder equity at the end of 2025 was negative by $8.028 billion, the result of historical large repurchases and accounting classification, not operating deterioration.) 20%+ ROIC means every unit of invested capital creates high returns, a hard indicator of strong unit economics.

  Cash conversion is the strongest part of the business. In 2025, operating cash flow was $12.233 billion, basically flat with 2024, and free cash flow was about $10.6 billion, roughly 94% of net income attributable to shareholders. The report judges that "profits are broadly real cash profits." Over the long term, operating cash flow is close to net income, capex intensity is low, and dividends are not maintained through share issuance. The money earned largely settles as cash.

  Where does the money go? Three destinations, with current-stage allocation relatively rational:

  First, dividends (the largest destination). In 2025, the dividend rose to $5.64 per share, and dividends paid were $8.6 billion; the current dividend yield is about 3.2%.

  Second, debt reduction. Leverage was elevated after the Swedish Match acquisition (total debt of about $51.9 billion in 2026 Q1, current net debt/EBITDA about 2.61 times, down from the 3.05 times cited by the report). The company is using more cash to deleverage rather than pursue aggressive buybacks. The report calls this "rational during a high-leverage period" and explicitly says that at the current valuation it "would rather see it repurchase less and pay down more debt."

  Third, supporting smoke-free capacity expansion. Capex mainly goes into smoke-free manufacturing capacity, but the absolute amount is low ($1.6 billion).

  One honest reservation: although unit economics are strong, "negative shareholder equity + elevated leverage + about $2.3 billion of restricted cash in Russia" means the balance sheet is not the "extremely financially stable" type of giant, but rather a combination of "high-quality operations + elevated leverage" (the report's checklist conclusion on the balance sheet is "uncertain"). This does not undermine the excellence of the unit economics themselves, but it reminds us that this good business is running with leverage.

  Overall judgment: PM has top-tier unit economics (67% gross margin, 26% ROIC, 94% cash conversion, low capex), and as it scales with smoke-free mix upgrade, unit economics continue to improve. The money it earns is rationally used for dividends, debt reduction, and smoke-free expansion. Using Baillie's four-question yardstick of "unit economics, incremental returns, scale effects, and where the money goes," PM scores among the highest in the whole report on this dimension. This is why the report repeatedly emphasizes that it is a good business "I would be willing to own long term on business quality." The problem has never been the business itself; it is the price.

  Jun 11, 2026
• QWhat conditions would need to hold simultaneously for it to rise fivefold in ten years? Are those conditions realistic? What expectations does today's share price imply?2/10

  A

  Bottom line: for PM to rise fivefold in ten years (about 17%/year total return), a set of conditions that are extremely hard for a mature nicotine company would need to hold at the same time: sustained high-speed earnings compounding + no retreat in the valuation premium, or even further expansion + friendly regulation throughout + smooth deleveraging. The probability of all these holding together is low. More importantly, today's share price of about $183 and 25.8 times PE already implies the optimistic expectation that "the smoke-free transition continues to deliver at high quality + the high premium does not fall back," not a discounted lottery ticket. So a ten-year fivefold return is unrealistic, and the current price leaves almost no room for "fivefold."

  First, break down the conditions required for a "ten-year fivefold" and score their realism one by one:

  Condition one: earnings compound at about 13%-15% for a long time (if valuation is unchanged, the fivefold return must come entirely from earnings). Realism is low. PM's historical revenue annualized at only about 6.6% in 2021-2025; in 2026 Q1, organic revenue growth was only 2.7%. Earnings can grow faster than revenue through smoke-free mix upgrade, and 2026 adjusted EPS guidance is up 10.9%-12.9% year on year, but that is a high point during the acceleration phase of the transformation and is hard to sustain for ten years. Cigarettes (58% of the company) will keep diluting overall growth through long-term decline. Sustaining 10%+ EPS growth for ten years is already quite optimistic; reaching 13%-15% is harder.

  Condition two: the valuation premium does not fall back, and even expands further. Realism is low, and the direction is unfavorable. PM is already at the upper end of peer valuation bands: under the report's framework, PM currently trades at 26.6x PE, 18.3x EV/EBITDA, and 27.6x P/FCF, a premium of about 94% to BAT (PE 13.7x) and about 73% to Altria (PE 15.4x). For a mature tobacco stock to maintain or expand this multiple over ten years rather than regress toward peers is itself a bet against mean reversion. In most cases, once the transformation matures, valuation converges rather than expands.

  Condition three: regulation remains friendly throughout, with no major reversal. Realism is medium-low. The report lists regulation as the first risk; cracks are already visible in reality. In 2026 Q1, U.S. competition and regulatory challenges caused ZYN shipments to fall 23.5% and U.S. segment net revenue to fall 30.8%. Over ten years, if the FDA or any major country materially tightens flavors, marketing, nicotine strength, or MRTP claims even once, both growth and the premium would come under pressure. Requiring regulation to have "no big incident" for ten years treats fragility as normal.

  Condition four: leverage is smoothly worked down, with no interest-rate shock. Realism is medium. Total debt was about $51.9 billion in 2026 Q1, and current net debt/EBITDA is about 2.61 times (improved from the 3.05x cited in the report, with investment-grade ratings still intact). This is the most achievable of the four conditions, but in an environment where the 10-year U.S. Treasury yield is about 4.52%, valuation tolerance for a high-leverage consumer stock is inherently constrained.

  Multiplying the four conditions: none is absurd in isolation, but their simultaneous fulfillment, high-speed earnings compounding, no retreat in valuation premium, no major regulatory incident for ten years, and cooperation from leverage and interest rates, is a low-probability event for a mature tobacco company sitting in the regulatory crosshairs. The report's own conclusion is consistent with this: even its optimistic scenario expects annualized returns of only 9%-11%/year, far below the about 17%/year needed for a fivefold return.

  Now answer the most important question: what expectations does today's share price imply? The answer is that today's price has already made "continued successful transformation + no retreat in the high premium" the base case. It is not giving you a fivefold lottery ticket. The report's three-scenario DCF is clear: using conservative 2025 Owner Earnings of about $10.6 billion as the anchor, intrinsic value per share is about $92 in the conservative scenario, about $134 in the neutral scenario, and about $178 in the optimistic scenario. The current market price of about $183 "is already roughly above the point estimate of the optimistic scenario and about 40% higher than the neutral scenario." In other words, today's market price requires you to believe all optimistic assumptions will come true. That means upside has already been pulled forward, and there is no room in the current price for the additional expectations needed for a fivefold return.

  Cross-check with Owner Earnings yield: the current starting Owner Earnings Yield is only about 3.7%, below the 10-year U.S. Treasury yield of about 4.52%. If you buy today, the initial cash yield is lower than a risk-free Treasury. All returns have to come from "transformation growth + no valuation compression." That is exactly the opposite payoff structure of a "ten-year five-bagger": upside is capped by valuation, while downside has real regulatory and de-premium risks.

  Overall judgment: a ten-year fivefold return requires four groups of optimistic conditions to hold simultaneously, and the probability is low. Today's roughly $183 share price already implies the two most important ones (high-quality transformation + sustained high premium), using up the upside in advance. By Baillie's test of "what must hold for a fivefold return + what today's price implies," PM's honest answer is: this is not a stock with room reserved for a fivefold return. It is a "good company, expensive price, upside already priced by the market" name. That is why the report assigns "Watch" and sets a reasonable buy range of $120-$145, well below the current price.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Does it not understand, look down on it, or fail to look far enough ahead? What would become the "narrative inflection point"?3/10

  A

  Bottom line: the default premise of this Baillie question is that "the market is underestimating a great growth stock, with unrecognized upside." But for PM, the honest answer is the opposite: the market has broadly understood it, respects it, and has seen its smoke-free transformation, paying a significant premium for it. There is no ignored positive insight waiting to be picked up. What the market may truly be "failing to look far enough ahead" on is instead downside tail risk (regulation, de-rating, terminal state). Therefore, the "narrative inflection point" is more likely to be a downward trigger than upward re-rating.

  First, prove that "the market has already realized it," because that is the factual basis for answering the question. If the market did not understand, PM would not trade at today's valuation: under the report's framework, PM is at 26.6x PE, 18.3x EV/EBITDA, and 27.6x P/FCF, a premium of about 94% to BAT and about 73% to Altria. The report states it plainly: "the market is willing to pay a large premium for PM's growth and transformation" and "the market has clearly seen these strengths." The current share price of about $183 is already above the point estimate of the report's optimistic DCF scenario (about $178). Sell-side consensus is also positive: currently the average analyst price target is about $193.86, with a "Buy" rating. All of this shows that the good news of the smoke-free transition has not only been seen by the market, but also priced in ahead of time.

  So, on the "does not understand / looks down on it / does not look far enough ahead" decomposition, the honest answers are:

  Does not understand? Not true. The smoke-free business is already a visible fact: 41.5% of net revenue in 2025 and 43% in 2026 Q1, IQOS has about 77% global heat-not-burn share, and surpassed Marlboro in 2026 Q1 to become the largest nicotine brand in its markets. This story has been fully researched and widely reported. There is no cognitive blind spot.

  Looks down on it? Also not true; the opposite is closer. The market is not "disliking" PM and assigning the usual low tobacco-stock multiple. It has pulled PM out of the tobacco group and priced it like a growth stock, giving it a premium far above peers. That is exactly why the report repeatedly emphasizes that "valuation is already at the upper end of the peer band or even higher." The market is not looking down on it; it is looking highly upon it.

  Does not look far enough ahead? This is the only one that might be true, but in the opposite direction. If something is not being looked far enough ahead, it is not upside (already priced), but downside tail risk: the market may be underestimating the nonlinear risk that if "the transformation is good rather than excellent" or "regulation throws cold water on it," valuation could quickly revert toward peers. The report expresses this clearly: "If the transformation continues to succeed, today's price may not lose much; but if the transformation is merely 'good' rather than 'excellent,' or regulation throws even some cold water on it, valuation could quickly revert toward peers."

  For that reason, PM's "narrative inflection points" are almost all downward triggers, not upward re-rating catalysts. The report already lists these inflection signals clearly and they can be used directly as a monitoring checklist:

  First, smoke-free share stalls. If the smoke-free revenue share stays around 40%-45% for a long time and cannot move toward 50%+, the "transformation growth" narrative will be replaced by a "high-quality low-growth tobacco" narrative.

  Second, ZYN loses its position in the U.S. If ZYN's value share clearly falls from about 2/3, and not because of active supply control, that would matter. This is exactly the yellow light that has already flashed in the most recent quarter: in 2026 Q1, ZYN shipments fell 23.5%, and U.S. segment net revenue fell 30.8% (the company attributes it to inventory normalization, with consumer offtake still up about 10%, but the market is highly sensitive to this). This is the most realistic near-term inflection-point candidate.

  Third, IQOS share peaks. If IQOS share in Japan/Europe stops rising or is persistently eroded, the growth center falls and the premium contracts with it.

  Fourth, regulatory/legal cold water. The FDA or major markets tighten flavors, marketing, or MRTP wording, or a long-tail legal event escalates, similar to the roughly C$32.5 billion Canadian Big Tobacco settlement. The report judges that "the market's premium multiple will be revised down before fundamentals are revised down."

  Fifth, capital allocation deteriorates. If the company resumes large buybacks at a high valuation instead of deleveraging, it would show a tilt toward "maintaining the EPS narrative" and shake trust in quality.

  Overall judgment: the honest answer for PM is that "the market has not missed it; the market has already fully priced it." There is no ignored positive perception gap, and the room for upward re-rating has been used up by the high premium. The real asymmetry is on the downside: narrative inflection points are more likely to come from smoke-free deceleration, regulatory cold water, and share loosening in ZYN/IQOS, triggering valuation reversion toward peers. By Baillie's yardstick of "why has the market not realized it + what is the narrative inflection point," PM is the opposite of a typical LTGG name. It is not a "dust-covered pearl the market cannot see," but a high-quality company the market sees very clearly and has already priced generously. This is the fundamental reason the report gives "Watch" rather than "Buy" and emphasizes that the main current risk is "paying too high a price for a good company."

  Jun 11, 2026